2025-12-9

Shanghai, China – December 2025 –InnovaRadi Therapeutics Co., Ltd. (“InnovaRadi”), a company dedicated to the development of innovative radiopharmaceuticals, announced that it has successfully completed its angel round financing led by Kairos Capital, with additional investment recently secured. The funds raised will primarily support the acceleration of non-clinical studies and clinical translation of the company’s core pipeline candidates, further advancing the development of precision oncology therapeutics centered on the alpha-emitting radionuclide astatine-211 (²¹¹At).

In collaboration with West China Hospital and Sichuan University, InnovaRadi has launched the world’s first investigator-initiated trial (IIT) applying ²¹¹At-MABG for the treatment of pediatric neuroblastoma.